AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01019343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Stimulation
Description: Constant-current, 0.1 to 0.5 ms square-wave single pulses of electrical stimulation will be delivered through standard bar electrodes to nerves of the upper limb or of the lower limb. To study somatosensory evoked potentials, for example, the stimulus intensity will be set at just above the motor threshold for evoking a slight limb movement. Location of the electrical stimulation will depend on the specific objective of the sub-study. Peripheral nerve stimulation might be delivered during other types of experiments as well.
Study NCT01019343 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: EMG
Description: EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
Study NCT01019343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMG
Description: EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
Study NCT01019343 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Trancutaneous spinal direct current stimulation (tsDCS)
Description: Direct current (DC) stimulation is a non invasive tool used to promote plasticity of the central nervous system. Recently, DC stimulation has been applied to the human spinal cord, and known as transcutaneous spinal direct current stimulation (tsDCS).
Study NCT01019343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trancutaneous spinal direct current stimulation (tsDCS)
Description: Direct current (DC) stimulation is a non invasive tool used to promote plasticity of the central nervous system. Recently, DC stimulation has been applied to the human spinal cord, and known as transcutaneous spinal direct current stimulation (tsDCS).
Study NCT01354574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index meals
Description: Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
Study NCT03003286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstuck and on Target (UOT)
Description: Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
Study NCT03003286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Teachers Supporting Students (PATSS)
Description: The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
Study NCT05657210 — intervention group
Intervention type: GENETIC
Intervention: Mutation
Study NCT04217135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: evidence-based medications vs. high-dose hydralazine + evidence-based medications
Description: randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
Study NCT04514718 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser
Description: low energy holmium laser
Study NCT01141803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apples
Description: 550g of apples/day
Study NCT01141803 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple pomace
Description: 22g apple pomace/day
Study NCT03385031 — intervention group
Intervention type: OTHER
Intervention: CBCT imaging
Description: CBCT imaging at first and last fraction of radiotherapy treatment
Study NCT03232398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Oral Tablet [Eliquis]
Description: Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
Study NCT03221868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: An exercise-based program following a 12-week periodization using mostly circuit-like activities.
Study NCT03221868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
Study NCT00666588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT00666588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT
Study NCT03232398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
Study NCT02766296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Emotional Working Memory Training
Description: This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.
Study NCT02766296 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Working Memory Training
Description: This training utilized a fixed dual 1-back training paradigm.
Study NCT00666588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00666588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT01235936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Different dose levels
Study NCT04661306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi (Sleep Healthy Using the Internet)
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
Study NCT00666588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01937494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: histamine-benzylic alcohol (magistral preparation)
Description: passive exposure to histamine during a bronchial hyperresponsiveness challenge
Study NCT04070963 — intervention group
Intervention type: OTHER
Intervention: HbA1C
Description: To take additional blood test of HbA1C once patient consented to the study
Study NCT00562614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-2101
Study NCT00562614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SLx-2101
Study NCT03809949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Opioid anesthesia
Description: To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
Study NCT03809949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nonopioid anesthesia
Description: To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
Study NCT03282045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysobact Complete Sprey
Description: Inhaling spray
Study NCT03282045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tantum Verde® Spray
Description: Inhaling spray
Study NCT03282045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngal® Oromucosal Spray
Description: Inhaling spray
Study NCT03282045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaling spray
Study NCT03805243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for somnonaute device
Description: test of sensors
Study NCT03805243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for uronaute device
Description: test of sensors
Study NCT03805243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for toconaute device
Description: test of sensors
Study NCT03805243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for neuronaute device
Description: test of sensors
Study NCT03805243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: test of sensors for cardioskin device
Description: test of sensors
Study NCT02061124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer 1600 mg TID for 7 days
Study NCT02061124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1600 mg TID for 7 days
Study NCT02711332 — intervention group
Intervention type: OTHER
Intervention: capillary blood sampling
Description: Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
Study NCT02711332 — intervention group
Intervention type: OTHER
Intervention: venous blood sampling
Description: Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
Study NCT00949364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles).
Study NCT01602185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (drug used like antitussive)
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Study NCT01602185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine (drug used in Alzheimer's disease)
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Study NCT01602185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (lactose)
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Study NCT04251923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retro pubic sling
Description: patient after hysterectomy will undergo retropubic sling surgery in the same setting. Retropubic sling will be inserted vaginally in the retropubic area following standard protocol.
Study NCT03068988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
Study NCT03068988 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: without mesenchymal stem cells
Description: rotator cuff surgery without mesenchymal stem cells
Study NCT03927196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: extended counseling
Description: Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
Study NCT03805672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Enoxaparin
Study NCT03805672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Enoxaparin
Study NCT02093169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Lu AF35700
Description: One 30 mg single dose for one day; orally
Study NCT02093169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Lu AF35700
Description: Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
Study NCT02630966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab 300 mg IV infusion
Study NCT04525664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 MG Oral Tablet
Description: 20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
Study NCT00903695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memory XL
Description: An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, \& acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
Study NCT00903695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study NCT01549860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIST Therapy
Description: Non-contact low frequency ultrasound therapy
Study NCT03025503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nipple stimulation
Study NCT02028624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
Study NCT02332278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early feeding
Description: Fluid diet four hours after cesarean section
Study NCT02630966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride IV infusion
Study NCT02230046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment A)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
Study NCT02230046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
Study NCT02230046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Treatment B)
Description: Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
Study NCT03677466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmaco-invasive strategy
Description: Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography.
Study NCT03677466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary PCI
Description: After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
Study NCT02924194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulation ON
Description: The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor.
Study NCT02924194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulation OFF
Description: The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor.
Study NCT02946567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noisy City information about hearing health care
Description: Participants will play the game Noisy City, which contains information about hearing health care.
Study NCT02946567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic Game
Description: Participants will play a generic game without any particular information about hearing health care.
Study NCT03466099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD001 Injection
Description: Intravitreal KVD001 Injection
Study NCT03466099 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham Procedure
Study NCT01975662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
Study NCT01975662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
Study NCT01671293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent remote care model
Description: A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer \& waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.